GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ArriVent BioPharma Inc (NAS:AVBP) » Definitions » ROA %

AVBP (ArriVent BioPharma) ROA % : -37.68% (As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is ArriVent BioPharma ROA %?

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. ArriVent BioPharma's annualized Net Income for the quarter that ended in Dec. 2024 was $-82.53 Mil. ArriVent BioPharma's average Total Assets over the quarter that ended in Dec. 2024 was $219.02 Mil. Therefore, ArriVent BioPharma's annualized ROA % for the quarter that ended in Dec. 2024 was -37.68%.

The historical rank and industry rank for ArriVent BioPharma's ROA % or its related term are showing as below:

AVBP' s ROA % Range Over the Past 10 Years
Min: -40.08   Med: -36.75   Max: -32.51
Current: -32.51

During the past 4 years, ArriVent BioPharma's highest ROA % was -32.51%. The lowest was -40.08%. And the median was -36.75%.

AVBP's ROA % is ranked better than
52.63% of 1501 companies
in the Biotechnology industry
Industry Median: -35.38 vs AVBP: -32.51

ArriVent BioPharma ROA % Historical Data

The historical data trend for ArriVent BioPharma's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ArriVent BioPharma ROA % Chart

ArriVent BioPharma Annual Data
Trend Dec21 Dec22 Dec23 Dec24
ROA %
- -32.68 -40.08 -36.75

ArriVent BioPharma Quarterly Data
Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
ROA % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -49.13 -28.38 -27.48 -34.86 -37.68

Competitive Comparison of ArriVent BioPharma's ROA %

For the Biotechnology subindustry, ArriVent BioPharma's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ArriVent BioPharma's ROA % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ArriVent BioPharma's ROA % distribution charts can be found below:

* The bar in red indicates where ArriVent BioPharma's ROA % falls into.



ArriVent BioPharma ROA % Calculation

ArriVent BioPharma's annualized ROA % for the fiscal year that ended in Dec. 2024 is calculated as:

ROA %=Net Income (A: Dec. 2024 )/( (Total Assets (A: Dec. 2023 )+Total Assets (A: Dec. 2024 ))/ count )
=-80.488/( (163.098+274.942)/ 2 )
=-80.488/219.02
=-36.75 %

ArriVent BioPharma's annualized ROA % for the quarter that ended in Dec. 2024 is calculated as:

ROA %=Net Income (Q: Dec. 2024 )/( (Total Assets (Q: Sep. 2024 )+Total Assets (Q: Dec. 2024 ))/ count )
=-82.532/( (163.098+274.942)/ 2 )
=-82.532/219.02
=-37.68 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Dec. 2024) net income data. ROA % is displayed in the 30-year financial page.


ArriVent BioPharma  (NAS:AVBP) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Dec. 2024 )
=Net Income/Total Assets
=-82.532/219.02
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-82.532 / 0)*(0 / 219.02)
=Net Margin %*Asset Turnover
=N/A %*0
=-37.68 %

Note: The Net Income data used here is four times the quarterly (Dec. 2024) net income data. The Revenue data used here is four times the quarterly (Dec. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


ArriVent BioPharma ROA % Related Terms

Thank you for viewing the detailed overview of ArriVent BioPharma's ROA % provided by GuruFocus.com. Please click on the following links to see related term pages.


ArriVent BioPharma Business Description

Traded in Other Exchanges
N/A
Address
18 Campus Boulevard, Suite 100, Newtown Square, Philadelphia, PA, USA, 19073
ArriVent BioPharma Inc is a clinical stage biopharmaceutical company dedicated to the identification, development and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize team's deep drug development experience to maximize the potential of lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.